Lenalidomide inhibits proliferation of Namalwa CSN.70 cells and interferes with Gab1 phosphorylation and adaptor protein complex assembly

Leukemia Research

Volumn 30, Issue 7, 2006, Pages 849-858

  Gandhi, Anita K ^a   Kang, Jian ^a   Naziruddin, Syedah ^a   Parton, Anastasia ^a   Schafer, Peter H ^a   Stirling, David I ^a  

^a CELGENE CORPORATION   (United States)

Author keywords

Gab1; Lenalidomide; Myelodysplastic syndromes; Revlimid

Indexed keywords

ADAPTOR PROTEIN; GRB2 ASSOCIATED BINDING PROTEIN 1; LENALIDOMIDE; PROTEIN; PROTEIN KINASE B; PROTEIN TYROSINE KINASE; TYROSINE KINASE RECEPTOR; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; B LYMPHOCYTE; CANCER CELL CULTURE; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL LINEAGE; CELL PROLIFERATION; CHROMOSOME DELETION 5; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN ASSEMBLY; PROTEIN PHOSPHORYLATION; T LYMPHOCYTE;

ADAPTOR PROTEIN COMPLEX 1; ADAPTOR PROTEINS, SIGNAL TRANSDUCING; APOPTOSIS; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; G0 PHASE; G1 PHASE; HUMANS; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTORS, ERYTHROPOIETIN; SIGNAL TRANSDUCTION; STRUCTURE-ACTIVITY RELATIONSHIP; THALIDOMIDE;

EID: 33744536515     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2006.01.010     Document Type: Article

References (43)

1. Corral L.G., Haslett P.A., Muller G.W., Chen R., Wong L.M., Ocampo C.J., et al. Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha. J Immunol 163 (1999) 380-386
2. LeBlanc R., Hideshima T., Catley L.P., Shringarpure R., Burger R., Mitsiades N., et al. Immunomodulatory drug costimulates T cells via the B7-CD28 pathway. Blood 103 (2004) 1787-1790
3. Schafer P.H., Gandhi A.K., Loveland M.A., Chen R.S., Man H.W., Schnetkamp P.P., et al. Enhancement of cytokine production and AP-1 transcriptional activity in T cells by thalidomide-related immunomodulatory drugs. J Pharmacol Exp Ther 305 (2003) 1222-1232
4. Haslett P.A., Hanekom W.A., Muller G., and Kaplan G. Thalidomide and a thalidomide analogue drug costimulate virus-specific CD8+ T cells in vitro. J Infect Dis 187 (2003) 946-955. Epub 2003 Mar 6.
5. Davies F.E., Raje N., Hideshima T., Lentzsch S., Young G., Tai Y.T., et al. Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood 98 (2001) 210-216
6. Dredge K., Marriott J.B., Macdonald C.D., Man H.W., Chen R., Muller G.W., et al. Novel thalidomide analogues display anti-angiogenic activity independently of immunomodulatory effects. Br J Cancer 87 (2002) 1166-1172
7. Hideshima T., Chauhan D., Shima Y., Raje N., Davies F.E., Tai Y.T., et al. Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood 96 (2000) 2943-2950
8. Richardson P.G., Schlossman R.L., Weller E., Hideshima T., Mitsiades C., Davies F., et al. Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood 100 (2002) 3063-3067
9. List A., Kurtin S., Roe D.J., Buresh A., Mahadevan D., Fuchs D., et al. Efficacy of lenalidomide in myelodysplastic syndromes. N Engl J Med 352 (2005) 549-557
10. Miura I., Graziano S.L., Cheng J.Q., Doyle L.A., and Testa J.R. Chromosome alterations in human small cell lung cancer: frequent involvement of 5q. Cancer Res 52 (1992) 1322-1328
11. Willman C.L., Sever C.E., Pallavicini M.G., Harada H., Tanaka N., Slovak M.L., et al. Deletion of IRF-1, mapping to chromosome 5q31.1, in human leukemia and preleukemic myelodysplasia. Science 259 (1993) 968-971
12. Mitsiades C.S., Mitsiades N., and Koutsilieris M. The Akt pathway: molecular targets for anti-cancer drug development. Curr Cancer Drug Targets 4 (2004) 235-256
13. Holgado-Madruga M., Emlet D.R., Moscatello D.K., Godwin A.K., and Wong A.J. A Grb2-associated docking protein in EGF- and insulin-receptor signalling. Nature 379 (1996) 560-564
14. Ong S.H., Hadari Y.R., Gotoh N., Guy G.R., Schlessinger J., and Lax I. Stimulation of phosphatidylinositol 3-kinase by fibroblast growth factor receptors is mediated by coordinated recruitment of multiple docking proteins. Proc Natl Acad Sci USA 98 (2001) 6074-6079
15. Weidner K.M., Di Cesare S., Sachs M., Brinkmann V., Behrens J., and Birchmeier W. Interaction between Gab1 and the c-Met receptor tyrosine kinase is responsible for epithelial morphogenesis. Nature 384 (1996) 173-176
16. Holgado-Madruga M., Moscatello D.K., Emlet D.R., Dieterich R., and Wong A.J. Grb2-associated binder-1 mediates phosphatidylinositol 3-kinase activation and the promotion of cell survival by nerve growth factor. Proc Natl Acad Sci USA 94 (1997) 12419-12424
17. Takahashi-Tezuka M., Yoshida Y., Fukada T., Ohtani T., Yamanaka Y., Nishida K., et al. Gab1 acts as an adapter molecule linking the cytokine receptor gp130 to ERK mitogen-activated protein kinase. Mol Cell Biol 18 (1998) 4109-4117
18. Podar K., Mostoslavsky G., Sattler M., Tai Y.T., Hayashi T., Catley L.P., et al. Critical role for hematopoietic cell kinase (Hck)-mediated phosphorylation of Gab1 and Gab2 docking proteins in interleukin 6-induced proliferation and survival of multiple myeloma cells. J Biol Chem 279 (2004) 21658-21665
19. Nishida K., Yoshida Y., Itoh M., Fukada T., Ohtani T., Shirogane T., et al. Gab-family adapter proteins act downstream of cytokine and growth factor receptors and T- and B-cell antigen receptors. Blood 93 (1999) 1809-1816
20. Rakhit S., Pyne S., and Pyne N.J. The platelet-derived growth factor receptor stimulation of p42/p44 mitogen-activated protein kinase in airway smooth muscle involves a G-protein-mediated tyrosine phosphorylation of Gab1. Mol Pharmacol 58 (2000) 413-420
21. Ingham R.J., Holgado-Madruga M., Siu C., Wong A.J., and Gold M.R. The Gab1 protein is a docking site for multiple proteins involved in signaling by the B cell antigen receptor. J Biol Chem 273 (1998) 30630-30637
22. Lecoq-Lafon C., Verdier F., Fichelson S., Chretien S., Gisselbrecht S., Lacombe C., et al. Erythropoietin induces the tyrosine phosphorylation of GAB1 and its association with SHC, SHP2, SHIP, and phosphatidylinositol 3-kinase. Blood 93 (1999) 2578-2585
23. Wickrema A., Uddin S., Sharma A., Chen F., Alsayed Y., Ahmad S., et al. Engagement of Gab1 and Gab2 in erythropoietin signaling. J Biol Chem 274 (1999) 24469-24474
24. Kapoor G.S., Zhan Y., Johnson G.R., and O'Rourke D.M. Distinct domains in the SHP-2 phosphatase differentially regulate epidermal growth factor receptor/NF-kappaB activation through Gab1 in glioblastoma cells. Mol Cell Biol 24 (2004) 823-836
25. Gillgrass A., Cardiff R.D., Sharan N., Kannan S., and Muller W.J. Epidermal growth factor receptor-dependent activation of Gab1 is involved in ErbB-2-mediated mammary tumor progression. Oncogene 22 (2003) 9151-9155
26. Kroger A., Koster M., Schroeder K., Hauser H., and Mueller P.P. Activities of IRF-1. J Interferon Cytokine Res 22 (2002) 5-14
27. Harada H., Kondo T., Ogawa S., Tamura T., Kitagawa M., Tanaka N., et al. Accelerated exon skipping of IRF-1 mRNA in human myelodysplasia/leukemia; a possible mechanism of tumor suppressor inactivation. Oncogene 9 (1994) 3313-3320
28. Dredge K., Horsfall R., Robinson S.P., Zhang L.H., Lu L., Tang Y., et al. Orally administered lenalidomide (CC-5013) is anti-angiogenic in vivo and inhibits endothelial cell migration and Akt phosphorylation in vitro. Microvasc Res 69 (2005) 56-63
29. Raje N., Kumar S., Hideshima T., Ishitsuka K., Chauhan D., Mitsiades C., et al. Combination of the mTOR inhibitor Rapamycin and RevlimidTM(CC-5013) has synergistic activity in multiple myeloma. Blood (2004)
30. Bouscary D., Pene F., Claessens Y.E., Muller O., Chretien S., Fontenay-Roupie M., et al. Critical role for PI 3-kinase in the control of erythropoietin-induced erythroid progenitor proliferation. Blood 101 (2003) 3436-3443
31. van den Akker E., van Dijk T., Parren-van Amelsvoort M., Grossmann K.S., Schaeper U., Toney-Earley K., et al. Tyrosine kinase receptor RON functions downstream of the erythropoietin receptor to induce expansion of erythroid progenitors. Blood 103 (2004) 4457-4465
32. Bartlett J.B., Tozer A., Stirling D., and Zeldis J.B. Recent clinical studies of the immunomodulatory drug (IMiD) lenalidomide. Br J Cancer 93 (2005) 613-619
33. List A.F.D.G.W., Bennett J.M., Giagounidis A.A.N., Raza A., Felman E.J., Powell B.L., et al. Hematologic and cytogenetic (CTG) response to lenalidomide (CC-5013;Revlimid) in transfusion-dependent (TD) MDS with chromosome 5q31.1 deletion: results of the multicenter MDS-003 study. Proceedings of the eighth international symposium on myelodysplastic syndromes 2005, 29, supplement 1 (2005) S14
34. Kim S.O., Loesch K., Wang X., Jiang J., Mei L., Cunnick J.M., et al. A role for Grb2-associated binder-1 in growth hormone signaling. Endocrinology 143 (2002) 4856-4867
35. Jadersten M., Forsbolm A.M., Emanuelsson E.K., Merup M., and Hellstrom-Lindberg E. Thalidomide analogue CC5013 (Revlimid) selectively inhibits in vitro growth of the malignant clone in myelodysplastic syndrome (MDS) patients with 5q deletion. Proceedings of the eighth international symposium on myelodysplastic syndromes 2005, 29, supplement 1 (2005) S6
36. Garcia-Guzman M., Dolfi F., Zeh K., and Vuori K. Met-induced JNK activation is mediated by the adapter protein Crk and correlates with the Gab1-Crk signaling complex formation. Oncogene 18 (1999) 7775-7786
37. Pratt J.C., Igras V.E., Maeda H., Baksh S., Gelfand E.W., Burakoff S.J., et al. Cutting edge: gab2 mediates an inhibitory phosphatidylinositol 3′-kinase pathway in T cell antigen receptor signaling. J Immunol 165 (2000) 4158-4163
38. Yamasaki S., Nishida K., Hibi M., Sakuma M., Shiina R., Takeuchi A., et al. Docking protein Gab2 is phosphorylated by ZAP-70 and negatively regulates T cell receptor signaling by recruitment of inhibitory molecules. J Biol Chem 276 (2001) 45175-45183
39. Teo S., Oliver S., Harden J., Stirling D., Thomas S., and Scheffler. A Phase I, single-blind, placebo-controlled, ascending, single oral dose, safety, tolerability and pharmacokinetic study of CDC-501, a novel immunomodulatory-oncologic agent, in healthy male subjects with a comparison of fed and fasted. Clin Pharmacol Therapeut 71 (2002) #WPIII-64
40. Holgado-Madruga M., and Wong A.J. Role of the Grb2-associated binder 1/SHP-2 interaction in cell growth and transformation. Cancer Res 64 (2004) 2007-2015
41. Korhonen J.M., Said F.A., Wong A.J., and Kaplan D.R. Gab1 mediates neurite outgrowth, DNA synthesis, and survival in PC12 cells. J Biol Chem 274 (1999) 37307-37314
42. Gual P., Giordano S., Williams T.A., Rocchi S., Van Obberghen E., and Comoglio P.M. Sustained recruitment of phospholipase C-gamma to Gab1 is required for HGF-induced branching tubulogenesis. Oncogene 19 (2000) 1509-1518
43. Holgado-Madruga M., and Wong A.J. Gab1 is an integrator of cell death versus cell survival signals in oxidative stress. Mol Cell Biol 23 (2003) 4471-4484